by Mark Curtis | Jun 25, 2014
. Welcome to your regenerative medicine deal review for the month of May. The space was quiet this past month; however, NeoStem did strike up a licensing deal with China-based Cellular Biomedicine Group to provide international reach to its newly acquired targeted...
by Lisa Willemse | Jun 3, 2014
> Bench to beside is a deceptively simple phrase. Only 15 characters and relatively jargon-free (assuming you know what bench and bedside are referring to), it’s rather easy to drop into documents or presentations without compromising space or time limits. And,...
by Nick Dragojlovic | May 26, 2014
> In a recent post on Signals, David Kent made the case for government-funded clinical trials of autologous stem cell therapies, since the lack of proven commercialization models in this area make it difficult to attract private investment. Another way of financing...
by Mark Curtis | May 22, 2014
. Welcome to your Update from the Clinic for the month of April. Athersys provides disappointing interim results for its MultiStem® cell therapy in ulcerative colitis patients. Sernova continues to demonstrate safety and biocompatability of its Cell Pouch technology...
by Lisa Willemse | May 21, 2014
> I’m not an academic, but I’ve been to many scientific conferences and read many more papers over the past 10 years or so. I know how important data is in research. I also know how important it is in communications (where visits, likes or shares are...
Comments